Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in CNS disorder therapeutics, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference.

Rhea-AI Summary

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in CNS disorder therapeutics, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. Sharon Mates, Ph.D., the company's CEO and Chairman, is scheduled to present on Tuesday, August 13, 2024, at 12:00 p.m. ET in Boston, MA.

Investors and interested parties can access the live and archived webcast of the presentation through the company's website at www.intracellulartherapies.com under the 'Events & Presentations' section in Investor Relations. Attendees are advised to log in 5-10 minutes early to register and install any necessary software for viewing the presentation.

Argus Session date unavailable

+1.07% session move Open Argus

Details

News Market Reaction – ITCI

The recorded move for ITCI in the trading session of this news was +1.07%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
646-930-4406

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Intra-Cellular Therapies (ITCI) presenting at the Canaccord Genuity 44th Annual Growth Conference?

Intra-Cellular Therapies (ITCI) is presenting on Tuesday, August 13, 2024, at 12:00 p.m. ET at the Canaccord Genuity 44th Annual Growth Conference in Boston, MA.

Who will be presenting for Intra-Cellular Therapies (ITCI) at the Canaccord Genuity conference?

Sharon Mates, Ph.D., the Chief Executive Officer and Chairman of Intra-Cellular Therapies, will be presenting at the conference.

How can investors access Intra-Cellular Therapies' (ITCI) presentation at the Canaccord Genuity conference?

Investors can access the live and archived webcast of the presentation through the 'Events & Presentations' section in the Investor Relations area of Intra-Cellular Therapies' website at www.intracellulartherapies.com.

What is the main focus of Intra-Cellular Therapies (ITCI) as a company?

Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders.